Structure Therapeutics
GPCR
26.68
-0.79
-2.88%
Structure Therapeutics
US · GPCR
#2815 by market cap
Listed 2023
26.68
-0.79
-2.88%
Live - 5344 symbols - heartbeat 93s ago
· 2026-10-08 08:29
Pre-market
26.71
+0.11%
After-hours
27.00
+1.20%
Overnight
26.78
+0.37%
- Market cap
- 1.90B
- P/E (TTM)i
- -8.81
- P/Bi
- 1.40
- EPSi
- -2.40
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on GPCR?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Rating change
H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Cuts Target Price to $70Market Newswire · 2026/6/11
-
Rating change
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $101Market Newswire · 2026/6/8
-
Company notice
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-SIHUAN PHARMACEUTICAL SIGNS COOPERATION AGREEMENT WITH U.S.-BASED ABALONE BIO TO JOINTLY DEVELOP A NEW-GENERATION INNOVATIVE THERAPY FOR WEIGHT LOSS AND MUSCLE GAIN, FURTHER DEEPENING ITS LAYOUT IN THE GPCR TARGET FIELDHKEX · 2025/10/30
-
Rating change
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $111Market Newswire · 2026/8/8
-
Rating change
William Blair Maintains Structure Therapeutics(GPCR.US) With Buy RatingMarket Newswire · 2026/6/8
-
Rating change
Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $126Market Newswire · 2026/8/10
-
Canaccord Genuity Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)TipRanks · 2026/9/9
-
CCORF Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $111Market Newswire · 2026/9/9
-
H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/9/9
-
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)TipRanks · 2026/9/9
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)TipRanks · 2026/8/10
-
Rating change
Citi Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $97Market Newswire · 2026/8/10
-
Rating change
J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $100Market Newswire · 2026/8/17
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: EnGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)TipRanks · 2026/9/9
-
Rating change
J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy RatingMarket Newswire · 2026/6/9
-
Rating change
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $97 to $145Market Newswire · 2026/8/7
-
Rating change
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)TipRanks · 2026/6/8
-
Rating change
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Cabaletta Bio (CABA) and Hinge Health, Inc. Class A (HNGE)TipRanks · 2026/6/8
-
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $125Market Newswire · 2026/9/9
-
Rating change
Jefferies Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)TipRanks · 2026/8/8
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 08:29:49 · For reference only, not investment advice and not tailored to your situation.